Revenue volatility remains extreme, evidenced by a $25.1 million inflow in 2025Q3 followed by a $10.5 million reversal in 2025Q4, indicating a lack of sustainable commercial operations.
| Metric | TTM | Jun'25 | Jun'24 | Jun'23 | Jun'22 | Jun'21 | Jun'20 | Jun'19 | Jun'18 | Jun'17 | Jun'16 | Jun'15 | Jun'14 | Jun'13 | Jun'12 | Jun'11 | Jun'10 | Jun'09 | Jun'08 | Jun'07 | Jun'06 | Jun'05 | Jun'04 | Jun'03 | Jun'02 | Jun'01 | Jun'00 | Jun'99 |
|---|
| Sales/Revenue | -10.47M | 15.65M | 0 | 0 | 263.61K | 0 | 32.06K | 2.68M | 2.76M | 4.13M | 5.21M | 5.08M | 18.02M | 1.49M | 1.15M | 3.4M | 2.54M | 2.91M | 1.08M | 693.21K | 484.09K | 225.36K | 0 | 692.83K | 907.33K | 599K | 0 | 0 |
| Revenue Growth % | -140.09% | - | - | -100% | - | -100% | -98.8% | -2.86% | -33.25% | -20.79% | 2.56% | -71.79% | 1106.21% | 29.65% | -66.12% | 33.73% | -12.7% | 170.48% | 55.41% | 43.2% | 114.81% | - | -100% | -23.64% | 51.47% | - | - | - |
| Cost of Goods Sold | 165.69K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 337.62K | 213.06K | 144.76K | 70.63K | 40.53K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.59% | 19.78% | 20.88% | 14.59% | 17.98% | - | - | - | - | - | - |
| Gross Profit | -10.64M | 15.65M | 0 | 0 | 263.61K | 0 | 32.06K | 2.68M | 2.76M | 4.13M | 5.21M | 5.08M | 18.02M | 1.49M | 1.15M | 3.4M | 2.54M | 2.91M | 1.08M | 693.21K | 484.09K | 225.36K | 0 | 692.83K | 907.33K | 599K | 0 | 0 |
| Gross Margin % | 101.58% | 100% | - | - | 100% | - | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | - | 100% | 100% | 100% | - | - |
| Gross Profit Growth % | - | - | - | -100% | - | -100% | -98.8% | -2.86% | -33.25% | -20.79% | 2.56% | -71.79% | 1106.21% | 29.65% | -66.12% | 33.73% | -12.7% | 170.48% | 55.41% | 43.2% | 114.81% | - | -100% | -23.64% | 51.47% | - | - | - |
| Operating Expenses | 15.55M | 16.78M | 26.79M | 33.09M | 21.6M | 8.96M | 6.23M | 13.43M | 24.04M | 14.93M | 26.89M | 25.3M | 21.59M | 19.76M | 13.37M | 13.88M | 9.95M | 8.59M | 7.99M | 9.15M | 6.11M | 4.52M | 3.3M | 3.35M | 2.62M | 1.77M | 540.72K | 28.7K |
| OpEx % of Revenue | - | 107.21% | - | - | 8195.17% | - | 19419.28% | 501.61% | 871.76% | 361.54% | 515.73% | 497.51% | 119.77% | 1322.56% | 1159.77% | 408.11% | 391.29% | 294.81% | 741.92% | 1320.18% | 1262.97% | 2003.59% | - | 484.17% | 288.6% | 295.33% | - | - |
| Selling, General & Admin | 7.18M | 7.77M | 0 | 13.41M | 0 | 4.24M | 3.33M | 6.55M | 4.97M | 5.72M | 7.89M | 6.64M | 4.33M | 4.51M | 3.82M | 3.34M | 2.37M | 2.25M | 3.64M | 3.17M | 1.86M | 1.2M | 726.57K | 434.61K | 524.12K | 143.67K | 115.56K | 0 |
| SG&A % of Revenue | - | 49.67% | - | - | - | - | 10396.44% | 244.58% | 180.15% | 138.52% | 151.22% | 130.53% | 24% | 301.63% | 331.31% | 98.15% | 93.06% | 77.13% | 337.83% | 456.98% | 383.38% | 530.32% | - | 62.73% | 57.76% | 23.98% | - | - |
| Research & Development | 6.72M | 9.01M | 14.1M | 19.67M | 16M | 4.33M | 4M | 6.29M | 18.55M | 18.61M | 18.5M | 17.78M | 16.74M | 14.76M | 9.32M | 9.72M | 7.3M | 6.54M | 7.29M | 5.47M | 5.05M | 3.4M | 2.17M | 2.51M | 1.85M | 1.04M | 399.31K | 0 |
| R&D % of Revenue | - | 57.54% | - | - | 6068.67% | - | 12489.64% | 234.74% | 672.62% | 450.61% | 354.72% | 349.7% | 92.91% | 987.69% | 808.39% | 285.77% | 286.86% | 224.44% | 677.12% | 789.12% | 1043.6% | 1508.35% | - | 362.95% | 203.93% | 173.72% | - | - |
| Other Operating Expenses | 791.38K | 0 | 12.69M | 0 | 5.61M | 386.74K | -1.11M | 596.83K | 523.58K | -9.4M | 510.24K | 878.88K | 515.47K | 496.71K | 231.29K | 823.01K | 289.4K | -196.98K | -2.94M | 513.55K | -793.95K | -79.06K | 397.48K | 405.2K | 244.13K | 584.73K | 25.84K | 28.7K |
| Operating Income | -26.19M | -1.13M | -26.79M | -33.09M | -21.34M | -8.96M | -6.19M | -10.76M | -21.28M | -10.8M | -21.68M | -20.21M | -3.56M | -18.27M | -12.21M | -10.48M | -7.41M | -6.01M | -7.13M | -8.6M | -5.7M | -4.33M | -3.3M | -2.66M | -1.71M | -1.17M | -540.72K | -28.7K |
| Operating Margin % | 250.04% | -7.21% | - | - | -8095.17% | - | -19319.28% | -401.61% | -771.76% | -261.54% | -415.73% | -397.51% | -19.77% | -1222.56% | -1059.77% | -308.11% | -291.29% | -206.4% | -661.69% | -1241.06% | -1177.56% | -1921.57% | - | -384.17% | -188.6% | -195.33% | - | - |
| Operating Income Growth % | - | 95.78% | 19.04% | -55.05% | -138.22% | -44.61% | 42.42% | 49.45% | -96.96% | 50.17% | -7.26% | -467.25% | 80.49% | -49.56% | -16.52% | -41.46% | -23.21% | 15.63% | 17.14% | -50.92% | -31.64% | -31.36% | -23.86% | -55.54% | -46.26% | -116.38% | -1783.78% | - |
| EBITDA | -25.3M | -121.9K | -25.79M | -32.09M | -20.23M | -7.68M | -4.52M | -9.05M | -19.61M | -9.06M | -19.74M | -18.5M | -2.06M | -17.02M | -11.52M | -9.54M | -6.46M | -4.98M | -6.05M | -7.63M | -4.73M | -3.93M | -2.93M | -2.2M | -1.47M | -1.04M | -514.88K | 0 |
| EBITDA Margin % | 241.61% | -0.78% | - | - | -7674.36% | - | -14082.87% | -337.83% | -711.27% | -219.36% | -378.57% | -363.81% | -11.44% | -1139.18% | -999.31% | -280.41% | -253.77% | -170.93% | -561.22% | -1100.91% | -977.22% | -1745.49% | - | -317.88% | -161.69% | -173.72% | - | - |
| EBITDA Growth % | -1311.82% | 99.53% | 19.62% | -58.62% | -163.42% | -70.08% | 50.1% | 53.86% | -116.43% | 54.1% | -6.73% | -797.02% | 87.88% | -47.79% | -20.72% | -47.77% | -29.62% | 17.62% | 20.78% | -61.32% | -20.26% | -34.04% | -33.25% | -50.12% | -40.98% | -102.11% | - | - |
| D&A (Non-Cash Add-back) | 883.39K | 1.01M | 992.56K | 998.17K | 1.11M | 1.28M | 1.68M | 1.71M | 1.67M | 1.74M | 1.94M | 1.71M | 1.5M | 1.25M | 696.72K | 942.51K | 954.42K | 1.03M | 1.08M | 971.56K | 969.82K | 396.8K | 362K | 459.24K | 244.13K | 129.39K | 25.84K | 28.7K |
| EBIT | -23.62M | -1.13M | -26.64M | -32.45M | -21.92M | -5.79M | -2.91M | -5.28M | -17.77M | -3.27M | -11.52M | -12.59M | 4.29M | -9.02M | -3.34M | -10.47M | -6.77M | -5.34M | -4.62M | -6.44M | -3.88M | -3.29M | -2.28M | -2.86M | -1.92M | -1.17M | -844.38K | -221.63K |
| Net Interest Income | 582.52K | 166.5K | 220.1K | 323.16K | -11.7K | -1.07M | -1.2M | -1.46M | -1.09M | -589K | -498.64K | 64.91K | -43.24K | 516.92K | 994.22K | 183.39K | 203.57K | 3.04K | 244.29K | 26.32K | 22.94K | 1.66K | -5.74K | 20.62K | 186.16K | 209.32K | 86.46K | 96.13K |
| Interest Income | 582.52K | 166.5K | 220.1K | 323.16K | 6.79K | 4.29K | 39.13K | 197.95K | 422.32K | 925.02K | 915.95K | 727.47K | 530.6K | 588.28K | 1.06M | 510.35K | 414.21K | 231.48K | 544.16K | 285.04K | 266.97K | 243.86K | 216.35K | 224.39K | 226.91K | 209.32K | 89.22K | 99.46K |
| Interest Expense | 0 | 0 | 0 | 0 | 18.48K | 1.08M | 1.24M | 1.66M | 1.51M | 1.51M | 1.41M | 662.56K | 573.84K | 71.36K | 65.96K | 326.96K | 210.64K | 228.43K | 299.88K | 258.72K | 244.03K | 242.2K | 222.1K | 203.76K | 40.75K | 0 | 2.76K | 3.34K |
| Other Income/Expense | -1.66M | 291.09K | 3.46M | 695.55K | -609.57K | 2.28M | 2.05M | 3.82M | 2M | 6.02M | 8.74M | 6.96M | 7.28M | 9.17M | 8.81M | -319.77K | 429.29K | 446.2K | 2.21M | 1.9M | 1.58M | 798.26K | 797.52K | -398.08K | -253.49K | -503.4K | -306.42K | -196.26K |
| Pretax Income | -27.85M | -838K | -23.32M | -32.39M | -21.95M | -6.68M | -4.14M | -6.94M | -19.28M | -4.79M | -12.94M | -13.25M | 3.72M | -9.09M | -3.41M | -10.8M | -6.98M | -5.57M | -4.92M | -6.7M | -4.12M | -3.53M | -2.5M | -3.06M | -1.96M | -1.67M | -847.14K | -224.96K |
| Pretax Margin % | 265.94% | -5.35% | - | - | -8326.42% | - | -12915.56% | -259.02% | -699.27% | -115.84% | -248.08% | -260.63% | 20.62% | -608.55% | -295.61% | -317.51% | -274.41% | -191.09% | -456.75% | -966.45% | -851.26% | -1567.35% | - | -441.62% | -216.54% | -279.37% | - | - |
| Income Tax | -296.4K | -468.37K | -130.73K | -209.47K | -191.79K | -140.82K | -142.65K | -165.79K | -852.96K | 401.57K | -534.22K | -251.42K | 697.02K | 34.84K | -197.16K | -802.01K | 0 | -29.77K | -343.51K | -2.08M | -116.08K | 0 | -3.57M | 0 | 0 | -3.28M | 0 | -337K |
| Effective Tax Rate % | 1.06% | 55.89% | 0.56% | 0.65% | 0.87% | 2.11% | 3.44% | 2.39% | 4.42% | -8.39% | 4.13% | 1.9% | 18.76% | -0.38% | 5.79% | 7.42% | 0% | 0.53% | 6.98% | 31% | 2.82% | 0% | 143.03% | 0% | 0% | 195.96% | 0% | 149.8% |
| Net Income | -27.55M | -369.63K | -23.19M | -32.18M | -21.76M | -6.53M | -4.89M | -6.77M | -18.43M | -5.19M | -12.4M | -13M | 3.02M | -9.13M | -3.21M | -10M | -6.98M | -5.54M | -4.58M | -4.62M | -4M | -3.53M | -2.5M | -3.06M | -1.96M | -1.67M | -847.14K | -224.96K |
| Net Margin % | 263.11% | -2.36% | - | - | -8253.66% | - | -15255.18% | -252.83% | -668.33% | -125.56% | -237.84% | -255.68% | 16.75% | -610.88% | -278.5% | -293.94% | -274.41% | -190.07% | -424.86% | -666.81% | -827.28% | -1567.35% | - | -441.62% | -216.54% | -279.37% | - | - |
| Net Income Growth % | -363.38% | 98.41% | 27.93% | -47.91% | -232.96% | -33.6% | 27.77% | 63.25% | -255.28% | 58.18% | 4.59% | -530.61% | 133.08% | -184.37% | 67.9% | -43.25% | -26.05% | -21% | 0.98% | -15.42% | -13.38% | -41.33% | 18.32% | -55.73% | -17.41% | -97.54% | -276.57% | - |
| Net Income (Continuing) | -27.55M | -369.63K | -23.19M | -32.18M | -21.76M | -6.53M | -4M | -6.77M | -18.43M | -5.19M | -12.4M | -13M | 3.02M | -9.13M | -3.21M | -10M | -6.98M | -5.54M | -4.58M | -4.62M | -4M | -3.53M | -2.5M | -3.06M | -1.96M | -1.67M | -847.14K | -224.96K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | -892.78K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.09 | -0.23 | -0.10 | -0.17 | -0.13 | -0.10 | -0.11 | -0.16 | -0.46 | -0.13 | -0.33 | -0.37 | 0.10 | -0.29 | -0.11 | -0.37 | -0.28 | -0.27 | -0.24 | -0.31 | -0.31 | -0.65 | -0.62 | -0.91 | -0.64 | -0.70 | -0.69 | -0.90 |
| EPS Growth % | 36.92% | -130% | 41.18% | -30.77% | -30% | 9.09% | 31.25% | 65.22% | -253.85% | 60.61% | 10.81% | -484.62% | 133.17% | -163.64% | 70.27% | -32.14% | -3.7% | -12.5% | 22.58% | 0% | 52.31% | -4.84% | 31.87% | -42.19% | 8.57% | -1.45% | 23.33% | - |
| EPS (Basic) | - | -0.23 | -0.10 | -0.17 | -0.13 | -0.10 | -0.11 | -0.16 | -0.46 | -0.13 | -0.33 | -0.37 | 0.10 | -0.29 | -0.11 | -0.37 | -0.28 | -0.27 | -0.24 | -0.31 | -0.31 | -0.65 | -0.62 | -0.91 | -0.64 | -0.70 | -0.69 | -0.90 |
| Diluted Shares Outstanding | 5.41M | 1.62M | 149.8M | 122.39M | 112.78M | 65M | 45.41M | 43.44M | 40.19M | 40.11M | 38.1M | 34.8M | 34.74M | 31.2M | 28.74M | 26.8M | 25.07M | 20.25M | 18.78M | 15.03M | 12.87M | 5.4M | 4.05M | 3.35M | 3.05M | 2.37M | 1.23M | 250.08K |
| Basic Shares Outstanding | 5.41M | 1.62M | 149.8M | 122.39M | 112.78M | 65M | 45.41M | 43.44M | 40.19M | 40.11M | 38.1M | 34.8M | 34.74M | 31.2M | 28.74M | 26.8M | 25.07M | 20.25M | 18.78M | 15.03M | 12.87M | 5.4M | 4.05M | 3.35M | 3.05M | 2.37M | 1.23M | 250.08K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Clinical Milestone Funding Dependency
As indicated by the company's financial history, Neuphoria Therapeutics' revenue trajectory is characterized by extreme volatility, highlighted by a $25.1 million inflow in 2025Q3 followed by a $10.5 million reversal in 2025Q4, suggesting that top-line figures are driven by non-recurring milestone events rather than sustainable commercial operations.
The absence of consistent revenue streams confirms that the firm functions as a clinical-stage R&D entity rather than a commercial enterprise. Investors should interpret these fluctuations as accounting adjustments related to licensing agreements, which provide little insight into the long-term viability of the company's neuropsychiatric pipeline.
Based on the reported income statement data, Neuphoria Therapeutics maintains a high fixed-cost structure, with R&D expenditures frequently exceeding $2.5 million per quarter, which suggests that the company's operational burn is accelerating even as it attempts to navigate early-stage clinical development and regulatory hurdles.
The persistent negative operating income, despite occasional revenue spikes, indicates that the firm is heavily reliant on external capital to fund its laboratory overhead and specialized labor. This cost structure implies that management must maintain a rigorous focus on capital efficiency to avoid premature dilution of equity holders.
According to recent financial filings, Neuphoria Therapeutics recorded a significant $163.7 million in stock-based compensation during 2025Q4, a figure that severely distorts the quality of reported net income and complicates the assessment of the company's true underlying operational performance and management's long-term incentive alignment.
This massive non-cash expense suggests that the company is utilizing equity-based compensation to preserve cash, which may mask the true economic cost of talent acquisition. Analysts should adjust for these items to better understand the cash-based burn rate and the potential for future shareholder dilution.
As reported in financial statements, the reliance on sporadic licensing revenue creates a precarious financial profile, as the company's inability to generate consistent operating income suggests that the current business model may be unsustainable without continuous, large-scale capital infusions or successful clinical trial outcomes.
Short-sellers would likely focus on the lack of recurring revenue and the high probability that the company will need to return to capital markets for funding. The current financial data warrants caution, as the firm's survival appears tethered to the successful execution of high-risk clinical milestones.
Quick answers to the most common questions about buying NEUP stock.
For fiscal year 2025, Neuphoria Therapeutics Inc. (NEUP) reported total revenue of $15.6M.
Neuphoria Therapeutics Inc. (NEUP) reported a net loss of $0.4M for the fiscal year ending 2025.
Neuphoria Therapeutics Inc. (NEUP) reported an operating income of $-1.1M, resulting in an operating profit margin of -7.2%. This margin reflects the operational efficiency of the business before interest and taxes.
Neuphoria Therapeutics Inc. (NEUP) generated $15.6M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.